Intellia Therapeutics Stock Forecast, Price & News

+2.14 (+2.57 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.18 million shs
Average Volume1.47 million shs
Market Capitalization$5.81 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Intellia Therapeutics logo

About Intellia Therapeutics

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.36 out of 5 stars

Medical Sector

796th out of 2,099 stocks

Diagnostic Substances Industry

15th out of 35 stocks

Analyst Opinion: 2.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions

Is Intellia Therapeutics a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Intellia Therapeutics stock.
View analyst ratings for Intellia Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Intellia Therapeutics?

Wall Street analysts have given Intellia Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Intellia Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Intellia Therapeutics' next earnings date?

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Intellia Therapeutics

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced its quarterly earnings results on Thursday, May, 6th. The company reported ($0.69) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.66) by $0.03. The business had revenue of $6.45 million for the quarter, compared to the consensus estimate of $8.57 million. Intellia Therapeutics had a negative net margin of 288.47% and a negative trailing twelve-month return on equity of 33.89%. Intellia Therapeutics's quarterly revenue was down 50.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.63) earnings per share.
View Intellia Therapeutics' earnings history

How has Intellia Therapeutics' stock been impacted by COVID-19?

Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NTLA stock has increased by 570.5% and is now trading at $85.29.
View which stocks have been most impacted by COVID-19

What price target have analysts set for NTLA?

14 equities research analysts have issued twelve-month target prices for Intellia Therapeutics' stock. Their forecasts range from $33.00 to $111.00. On average, they anticipate Intellia Therapeutics' share price to reach $79.00 in the next twelve months. This suggests that the stock has a possible downside of 7.4%.
View analysts' price targets for Intellia Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Intellia Therapeutics' key executives?

Intellia Therapeutics' management team includes the following people:
  • Dr. John M. Leonard, Pres, CEO & Director (Age 64, Pay $912.79k)
  • Mr. Glenn G. Goddard, Exec. VP, CFO & Treasurer (Age 50, Pay $562.45k)
  • Dr. Andrew D. Schiermeier, Exec. VP & COO (Age 51, Pay $637.38k)
  • Dr. Laura Sepp-Lorenzino, Exec. VP & Chief Scientific Officer (Age 60, Pay $609.38k)
  • Dr. David Lebwohl M.D., Exec. VP & Chief Medical Officer
  • Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 48)
  • Dr. Rachel Haurwitz, Co-Founder (Age 35)
  • Dr. Andrew May, Founder and Member of Scientific Advisor Board
  • Dr. Jennifer A. Doudna, Founder & Member of Scientific Advisor Board (Age 57)
  • Dr. Derrick J. Rossi, Founder & Member of Scientific Advisor Board

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics CEO John Leonard, M.D. on John Leonard, M.D. has an approval rating of 73% among Intellia Therapeutics' employees.

Who are some of Intellia Therapeutics' key competitors?

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (14.10%), BlackRock Inc. (7.74%), Nikko Asset Management Americas Inc. (7.11%), Sumitomo Mitsui Trust Holdings Inc. (7.10%), Price T Rowe Associates Inc. MD (3.41%) and Alliancebernstein L.P. (2.58%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, Caroline Dorsa, Jean Francois Formela, John M Leonard, Jose E Rivera and Perry A Karsen.
View institutional ownership trends for Intellia Therapeutics

Which institutional investors are selling Intellia Therapeutics stock?

NTLA stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Morgan Stanley, Chevy Chase Trust Holdings Inc., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Capital Impact Advisors LLC, Royal Bank of Canada, and UBS Group AG. Company insiders that have sold Intellia Therapeutics company stock in the last year include Andrew Schiermeier, Caroline Dorsa, Jean Francois Formela, John M Leonard, Jose E Rivera, and Perry A Karsen.
View insider buying and selling activity for Intellia Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Intellia Therapeutics stock?

NTLA stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Jennison Associates LLC, Lord Abbett & CO. LLC, Nomura Holdings Inc., JPMorgan Chase & Co., PFM Health Sciences LP, Compagnie Lombard Odier SCmA, and BlackRock Inc..
View insider buying and selling activity for Intellia Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $85.29.

How much money does Intellia Therapeutics make?

Intellia Therapeutics has a market capitalization of $5.81 billion and generates $57.99 million in revenue each year. The company earns $-134,230,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis.

How many employees does Intellia Therapeutics have?

Intellia Therapeutics employs 312 workers across the globe.

What is Intellia Therapeutics' official website?

The official website for Intellia Therapeutics is

Where are Intellia Therapeutics' headquarters?

Intellia Therapeutics is headquartered at 40 Erie Street Suite 130, Cambridge MA, 02139.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.